Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0253 | 0.4385 | 0.5 |
Schistosoma mansoni | jun-related protein | 0.0205 | 0.056 | 0.5 |
Brugia malayi | hypoxia-induced factor 1 | 0.0297 | 0.7983 | 0.7983 |
Brugia malayi | bZIP transcription factor family protein | 0.0253 | 0.4385 | 0.4385 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.056 | 0.5 |
Loa Loa (eye worm) | hypoxia-induced factor 1 | 0.0297 | 0.7983 | 0.6734 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0253 | 0.4385 | 0.5 |
Echinococcus granulosus | jun protein | 0.0253 | 0.4385 | 0.5 |
Onchocerca volvulus | 0.0198 | 0 | 0.5 | |
Echinococcus multilocularis | jun protein | 0.0253 | 0.4385 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0322 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.06 ug ml-1 | Antibacterial activity against Staphylococcus aureus ATCC 25923 | ChEMBL. | No reference |
MIC (functional) | = 0.5 ug ml-1 | Antibacterial activity against Staphylococcus aureus MR 0.13 | ChEMBL. | No reference |
MIC (functional) | = 1 ug ml-1 | Antibacterial activity against Escherichia coli DC2, hyperpermeable strain | ChEMBL. | No reference |
MIC (functional) | = 1 ug ml-1 | Antibacterial activity against Escherichia coli DC2, hyperpermeable strain | ChEMBL. | No reference |
MIC (functional) | > 32 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 25922 | ChEMBL. | No reference |
MIC (functional) | > 32 ug ml-1 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | ChEMBL. | No reference |
MIC (functional) | > 32 ug ml-1 | Antibacterial activity against Pseudomonas aeruginosa VR5 | ChEMBL. | No reference |
MIC (functional) | > 32 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 25922 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.